Application and clinical efficacy of Sufu medical chitosan hydrogel dressing in radiation skin damage caused by radiotherapy for cervical cancer
- PMID: 36415280
- PMCID: PMC9676621
- DOI: 10.12669/pjms.38.8.5569
Application and clinical efficacy of Sufu medical chitosan hydrogel dressing in radiation skin damage caused by radiotherapy for cervical cancer
Abstract
Objectives: To investigate the benefits of Sufu medical chitosan hydrogel dressing(Sufu) in the prevention and control of radiation skin damage during radiotherapy for cervical cancer as a combined modality.
Methods: Ninety-seven cervical cancer patients who underwent radiotherapy at the Cancer Hospital of China Medical University between May 2017 and November 2018 were recruited according to given inclusion and exclusion criteria. The patients were assigned to a control group (n=48, washing the perineal area with normal saline) and an observation group (n=49, application of Sufu onto the site of radiotherapy in addition to washing the perineal area with normal saline). The treatment regimens for the two groups continued until the end of radiotherapy. A comparison of the RTOG (Radiation Therapy Oncology Group) grading of acute radiation-induced skin reactions (ARISRs), pain intensity (measured by the verbal rating scale (VRS)) and post-treatment wound healing was drawn between the two groups.
Results: In the observation group, 81.6% (40/49) of the patients had radiation dermatitis, which was significantly lower than the incidence rate (95.8%, 46/48) in the control group (P <0.05). The observation group was at higher risk of radiation dermatitis when given a high radiation dose, while the control group was more likely to have radiation dermatitis when administered with a moderate radiation dose (P <0.05). The median time of occurrence of pain and the median time of onset of skin reactions were significantly later in the observation group as compared with the control group (P <0.05, respectively). In the observation group, the pain relief rate was 92.50% at Day-3, and the wound healing rate was 95.0% at Day-7, significantly higher than in the control group (73.9% and 80.4%) (P <0.05, respectively).
Conclusions: During radiotherapy for cervical cancer, Sufu can effectively prevent and control radiation-induced skin and mucous membrane damage, delay the onset of radiation dermatitis and substantially reduce the incidence rate, relieve radiation dermatitis and pain and promote wound healing.
Keywords: Cervical cancer; Clinical efficacy; Radiation dermatitis; Sufu.
Copyright: © Pakistan Journal of Medical Sciences.
Conflict of interest statement
Conflicts of interest: None.
Similar articles
-
What is the appropriate skin cleaning method for nasopharyngeal cancer radiotherapy patients? A randomized controlled trial.Support Care Cancer. 2022 May;30(5):3875-3883. doi: 10.1007/s00520-022-06835-8. Epub 2022 Jan 17. Support Care Cancer. 2022. PMID: 35037118 Clinical Trial.
-
An Aloe Vera-Based Cosmeceutical Cream Delays and Mitigates Ionizing Radiation-Induced Dermatitis in Head and Neck Cancer Patients Undergoing Curative Radiotherapy: A Clinical Study.Medicines (Basel). 2017 Jun 24;4(3):44. doi: 10.3390/medicines4030044. Medicines (Basel). 2017. PMID: 28930258 Free PMC article.
-
Prophylactic Use of Mepitel® Film to Prevent Radiation-Induced Moist Desquamation in Cancer Patients.Cureus. 2023 Jul 20;15(7):e42186. doi: 10.7759/cureus.42186. eCollection 2023 Jul. Cureus. 2023. PMID: 37601988 Free PMC article. Review.
-
Protection of sildenafil citrate hydrogel against radiation-induced skin wounds.Burns. 2020 Aug;46(5):1157-1169. doi: 10.1016/j.burns.2019.11.020. Epub 2019 Dec 20. Burns. 2020. PMID: 31870570
-
The Effect of Sanyrene Liquid Dressing in Preventing Radiation Dermatitis: A Systematic Review and Meta-analysis.Adv Skin Wound Care. 2022 Nov 1;35(11):1-8. doi: 10.1097/01.ASW.0000889852.91765.ad. Adv Skin Wound Care. 2022. PMID: 36264754
Cited by
-
Systematic review of the tools and outcomes for the assessment of acute radiation dermatitis severity.Clin Transl Radiat Oncol. 2025 May 9;53:100977. doi: 10.1016/j.ctro.2025.100977. eCollection 2025 Jul. Clin Transl Radiat Oncol. 2025. PMID: 40502854 Free PMC article. Review.
-
Retrospective analysis of efficacy and safety of recombinant human Rh-endostatinstatin combined with concurrent radiotherapy for cervical cancer.Pak J Med Sci. 2024 Sep;40(8):1695-1701. doi: 10.12669/pjms.40.8.8770. Pak J Med Sci. 2024. PMID: 39281232 Free PMC article.
References
-
- Hashmi H, Maqbool A, Ahmed S, Ahmed A, Sheikh K, Ahmed A. Concurrent Cisplatin-Based Chemoradiation in Squamous Cell Carcinoma of Cervix. J Coll Physicians Surg Pak. 2016;26(4):302–5. PMID:27097702. - PubMed
-
- Wuerthner BA, Avila-Wallace M. Cervical cancer:Screening, management, and prevention. Nurse Pract. 2016;41(9):18–23. doi:10.1097/01. NPR.0000490390.43604.5f. - PubMed
-
- Hafiz A, Abbasi AN, Ali N, Khan KA, Qureshi BM. Frequency and Severity of Acute Toxicity of Pelvic Radiotherapy for Gynecological Cancer. J Coll Physicians Surg Pak. 2015 Nov;25(11):802–6. PMID:26577965. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous